Refining Treatment Approaches for Chronic Lymphocytic Leukemia
A discussion about several topics pertaining to the treatment of CLL including the latest research in the field and the impact of recent clinical trial data on making treatment decisions for your patients.
EP. 1: CLL: Evolution of Treatment
John Allan, MD, Weill Cornell Medicine
William Wierda, MD, PhD, leads a panel of experts in a discussion pertaining to the treatment of chronic lymphocytic leukemia (CLL), beginning with the evolving treatment landscape.
EP. 2: Molecular Testing for Newly Diagnosed CLL
John Allan, MD, Weill Cornell Medicine
Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).
EP. 5: Long-Term Experience With Ibrutinib in CLL
John Allan, MD, Weill Cornell Medicine
Jennifer Woyach, MD, discusses her experience using ibrutinib for chronic lymphocytic leukemia (CLL) in the first-line setting.
EP. 6: BTK Inhibitors as Frontline Treatment for CLL
John Allan, MD, Weill Cornell Medicine
Leukemia experts provide their personal experience using Bruton tyrosine kinase (BTK) inhibitors to treat patients with chronic lymphocytic leukemia (CLL) in the first-line setting.
EP. 7: Safety and Efficacy of BTK Inhibitors in CLL
John Allan, MD, Weill Cornell Medicine
A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).
EP. 9: ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL
John Allan, MD, Weill Cornell Medicine
An overview of the h ALPINE trial of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
EP. 10: BCL2 Inhibitors in Previously Untreated CLL
John Allan, MD, Weill Cornell Medicine
Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.
EP. 11: CLL Therapies: Novel Combinations
John Allan, MD, Weill Cornell Medicine
John Allen, MD, provides an overview of data looking at emerging combinations as initial therapy for chronic lymphocytic leukemia (CLL).
EP. 12: CLL: GLOW Trial Overview
John Allan, MD, Weill Cornell Medicine
Steven Coutre, MD, provides an overview of the phase 3 GLOW trial, as well as other novel and emerging combinations for the treatment of chronic lymphocytic leukemia (CLL).
EP. 13: CLL: BTK Inhibitors in the R/R Setting
John Allan, MD, Weill Cornell Medicine
Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.
